EyePoint公布Lugano试验顶线数据——湿性AMD候选药物Duravyu™ 2.7Mg两项关键III期临床研究首项结果揭晓

美股速递08-17

EyePoint Pharmaceuticals今日宣布，其备受关注的关键性III期临床试验Lugano研究的顶线数据已正式出炉。这项研究是评估Duravyu™ 2.7Mg在湿性年龄相关性黄斑变性（wet AMD）治疗中疗效与安全性的两项 pivotal 试验中的第一项，其结果的公布标志着该公司在眼科治疗领域迈出了至关重要的一步。

作为眼科药物研发领域的深耕者，EyePoint此次披露的数据将为Duravyu™ 2.7Mg的后续监管申报奠定坚实基础。Lugano研究的完整数据将在即将召开的科学会议上进行详细展示，届时业界将得以更全面地审视该候选药物的临床表现。湿性AMD作为一种可导致严重视力丧失的进行性眼病，长期以来一直是眼科治疗的重点与难点，因此这项研究的进展受到投资者和临床医生的广泛关注。

随着Lugano研究的尘埃落定，行业目光现已转向第二项关键性III期试验的最终结果，该数据的问世将进一步明确Duravyu™ 2.7Mg在湿性AMD治疗格局中的潜在定位。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1174905289?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-17 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174905289","market":"us","top_or_hot":-1,"title":"EyePoint公布Lugano试验顶线数据——湿性AMD候选药物Duravyu™ 2.7Mg两项关键III期临床研究首项结果揭晓","media":"美股速递","content":"<p>EyePoint Pharmaceuticals今日宣布，其备受关注的关键性III期临床试验Lugano研究的顶线数据已正式出炉。这项研究是评估Duravyu™ 2.7Mg在湿性年龄相关性黄斑变性（wet AMD）治疗中疗效与安全性的两项 pivotal 试验中的第一项，其结果的公布标志着该公司在眼科治疗领域迈出了至关重要的一步。</p>\n<p>作为眼科药物研发领域的深耕者，EyePoint此次披露的数据将为Duravyu™ 2.7Mg的后续监管申报奠定坚实基础。Lugano研究的完整数据将在即将召开的科学会议上进行详细展示，届时业界将得以更全面地审视该候选药物的临床表现。湿性AMD作为一种可导致严重视力丧失的进行性眼病，长期以来一直是眼科治疗的重点与难点，因此这项研究的进展受到投资者和临床医生的广泛关注。</p>\n<p>随着Lugano研究的尘埃落定，行业目光现已转向第二项关键性III期试验的最终结果，该数据的问世将进一步明确Duravyu™ 2.7Mg在湿性AMD治疗格局中的潜在定位。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint公布Lugano试验顶线数据——湿性AMD候选药物Duravyu™ 2.7Mg两项关键III期临床研究首项结果揭晓</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint公布Lugano试验顶线数据——湿性AMD候选药物Duravyu™ 2.7Mg两项关键III期临床研究首项结果揭晓\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-17 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>EyePoint Pharmaceuticals今日宣布，其备受关注的关键性III期临床试验Lugano研究的顶线数据已正式出炉。这项研究是评估Duravyu™ 2.7Mg在湿性年龄相关性黄斑变性（wet AMD）治疗中疗效与安全性的两项 pivotal 试验中的第一项，其结果的公布标志着该公司在眼科治疗领域迈出了至关重要的一步。\n作为眼科药物研发领域的深耕者，EyePoint此次披露的数据将为...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1174905289","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174905289","pubTimestamp":1786964507,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"EyePoint Pharmaceuticals今日宣布，其备受关注的关键性III期临床试验Lugano研究的顶线数据已正式出炉。这项研究是评估Duravyu 2.7Mg在湿性年龄相关性黄斑变性治疗中疗效与安全性的两项 pivotal 试验中的第一项，其结果的公布标志着该公司在眼科治疗领域迈出了至关重要的一步。随着Lugano研究的尘埃落定，行业目光现已转向第二项关键性III期试验的最终结果，该数据的问世将进一步明确Duravyu 2.7Mg在湿性AMD治疗格局中的潜在定位。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","EYPT":"EyePoint","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"EyePoint announces top-line data from Lugano trial-wet AMD drug candidate Duravyu ™ The first results of two pivotal phase III clinical studies of 2.7Mg announced","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"EyePoint Pharmaceuticals今日宣布，其备受关注的关键性III期临床试验Lugano研究的顶线数据已正式出炉。这项研究是评估Duravyu™ 2.7Mg在湿性年龄相关性黄斑变性（wet AMD）治疗中疗效与安全性的两项 pivotal 试验中的第一项，其结果的公布标志着该公司在眼科治疗领域迈出了至关重要的一步。\n作为眼科药物研发领域的深耕者，EyePoint此次披露的数据将为Duravyu™ 2.7Mg的后续监管申报奠定坚实基础。Lugano研究的完整数据将在即将召开的科学会议上进行详细展示，届时业界将得以更全面地审视该候选药物的临床表现。湿性AMD作为一种可导致严重视力丧失的进行性眼病，长期以来一直是眼科治疗的重点与难点，因此这项研究的进展受到投资者和临床医生的广泛关注。\n随着Lugano研究的尘埃落定，行业目光现已转向第二项关键性III期试验的最终结果，该数据的问世将进一步明确Duravyu™ 2.7Mg在湿性AMD治疗格局中的潜在定位。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174905289","isCrawlerRequest":true}